Spectral Medical Inc (TSE:EDT) Director Kevin Arnold Giese purchased 50,000 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was bought at an average cost of C$0.75 per share, with a total value of C$37,500.00. Following the completion of the transaction, the director now directly owns 3,426,336 shares in the company, valued at approximately C$2,569,752.
TSE EDT traded up C$0.02 on Friday, reaching C$0.75. The company had a trading volume of 42,200 shares, compared to its average volume of 94,059. The stock has a market capitalization of $155.81 million and a P/E ratio of -57.69. The company’s fifty day moving average is C$0.75 and its 200 day moving average is C$0.55. Spectral Medical Inc has a 52-week low of C$0.30 and a 52-week high of C$0.85. The company has a quick ratio of 3.64, a current ratio of 4.24 and a debt-to-equity ratio of 21.26.
Spectral Medical (TSE:EDT) last released its quarterly earnings results on Thursday, November 14th. The company reported C($0.01) EPS for the quarter. The company had revenue of C$0.53 million during the quarter. On average, research analysts expect that Spectral Medical Inc will post -0.06 EPS for the current year.
Spectral Medical Inc focuses on the development and commercialization of treatment for septic shock in North America. The company markets Endotoxin Activity Assay, a rapid diagnostic test for the detection of components of gram negative bacterial cell wall in Europe and Canada; and Toraymyxin, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream in Europe, Canada, and Japan.
Further Reading: Portfolio Manager
Receive News & Ratings for Spectral Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Medical and related companies with MarketBeat.com's FREE daily email newsletter.